Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism

American Journal of Hematology

Volumn 58, Issue 4, 1998, Pages 299-305

  Richardson, D R ^a   Ponka, P ^b,c  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Desferrioxamine; Iron chelation therapy; Iron chelators; Iron overload disease

Indexed keywords

BATHOPHENANTHROLINE DISULFONIC ACID; CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; EDETIC ACID; EDETIC ACID DERIVATIVE; ETHYLENEDIAMINE N,N' BIS(2 HYDROXYPHENYLACETIC ACID); FERRIC ION; FERROUS ION; HYDRAZONE DERIVATIVE; IRON; N,N' BIS(O HYDROXYBENZYL) ETHYLENEDIAMINE DIACETIC ACID DIMETHYL ESTER; N,N' BIS(O HYDROXYBENZYL)ETHYLENEDIAMINE DIACETIC ACID; N,N' ETHYLENEBIS(O HYDROXYPHENYLGLYCINE) DIMETHYL ESTER; PENTETIC ACID; PHENOL DERIVATIVE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; SIDEROPHORE; UNCLASSIFIED DRUG;

ANEMIA; BETA THALASSEMIA; CLINICAL TRIAL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

DEFEROXAMINE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; RETICULOCYTES;

EID: 0031869315     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199808)58:4<299::AID-AJH9>3.0.CO;2-L     Document Type: Review

References (90)

1. Olivieri NF: Long-term therapy with deferiprone. Acta Haematol 95: 37, 1996.
2. Diav-Citrin O, Koren G: Oral iron chelation with deferiprone. Pediatr Clin North Am 44:235, 1997.
3. Olivieri NF, Brittenham GM: Iron chelation therapy and the treatment of thalassemia. Blood 89:739, 1997.
4. Hershko C: Control of disease by selective iron depletion: A novel therapeutic strategy utilizing iron chelators. Bailliére's Clin Haematol 7:965, 1994.
5. Blatt J, Stitely S: Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res 47:1749, 1987.
6. Becton DL, Bryles P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 48:7189, 1988.
7. Donfrancesco A, Deb G, De Sio L, Cozza R, Castellano A: Role of desferrioxamine in tumor therapy. Acta Haematol 95:66, 1996.
8. Richardson DR: Iron chelators as effective anti-proliferative agents. Can J Physiol Pharmacol 75:1164, 1997.
9. Richardson DR: Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Leuk Lymphoma 1998 (in press).
10. Yinnon AM, Theanacho EN, Grady RW, Spira DT, Hershko C: Antimalarial effect of HBED and other phenolic and catecholic iron chelators. Blood 74:2166, 1989.
11. Tsafack A, Loyevsky M, Ponka P, Cabantchik ZI: Mode of action of iron(III) chelators as anti-malarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. J Lab Clin Med 127:574, 1996.
12. Golenser J, Domb A, Teomin D, Tsafack A, Nisim O, Ponka P, Eling W, Cabantchik ZI. The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release. J Pharmacol Exp Ther 281:1127, 1997.
13. Schulman HM, Hermes-Lima M, Wang EM, Ponka P: In vitro antioxidant properties of the iron chelator pyridoxal isonicotinoyl hydrazone and some of its analogues. Redox Rep 1:373, 1996.
14. Bhattacharya M, Ponka P, Hardy P, Hanna N, Varma DR, Lachapelle P, Chemtob S: Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone. Free Radical Biol Med 22:11, 1997.
15. Gehlbach P, Purple RL: Enhancement of retinal recovery by conjugated deferoxamine after ischaemia-reperfusion. Invest Ophthalol Visual Sci 35:669, 1994.
16. Karwatowska-Prokopczuk E, Czarnowska E, Prokopczuk A: Combined therapy with dimethylthiourea, diltiazem and amiloride/ dimethylamiloride in the ischemic/reperfused heart. Cardiovasc Res 30:70, 1995.
17. Bel A, Martinod E, Menasche P: Cardioprotective effect of desferrioxamine. Acta Haematol 95:63, 1996.
18. Magro AM, Brai M: Evidence for lipoxygenase activity in induction of histamine release from rat peritoneal mast cells by chelated iron. Immunology 49:1, 1983.
19. Shalit M, Tedeschi A, Miadonna A, Levi-Schaffer F: Desferal (desferrioxamine): A novel activator of connective tissue-type mast cells. J Allergy Clin Immunol 88:854, 1991.
20. Lombardo T, Ferro G, Frontini V, Percolla S: High dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration. Am J Hematol 51:90, 1996.
21. Baker E: Biologic screens for iron chelators. Birth Defects 23:49, 1988.
22. Kontoghiorghes GJ: The design of orally active iron chelators for the treatment of thalassemia. Ph.D Thesis, University of Essex, Colchester, U.K., British Library microfilm no. D66194/86, 1982.
23. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G: Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332:918, 1995.
24. al Refaie FN, Wonke B, Hoffbrand AV: Deferiprone-associated myelotoxicity. Eur J Haematol 53:298, 1994.
25. al Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B: Results of long-term deferiprone (L1) therapy: A report by the international study group on oral iron chelators. Br J Haematol 91:224, 1995.
26. Olivieri NF for the Toronto Iron Chelation Group: Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major. Blood 88(Suppl 1):651a, 1996 (abstr).
27. Olivieri NF for the Toronto Iron Chelation Group: Long-term follow-up of body iron in patients with thalassemia major during therapy with the orally active iron chelator deferiprone (L1). Blood 88(Suppl 1): 310a, 1996 (abstr).
28. Castriota-Scanderberg A, Sacco M: Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). Br J Hematol 96:254, 1997.
29. Dogherty P, Einarson T, Koren G, Sher G: The effectiveness of deferiprone in thalassemia. Blood 90:894, 1997.
30. Chaberek S, Martell AE: Organic Sequestering Agents. New York: John Wiley and Sons, Inc., 1969.
31. Neilands JB: Microbial iron transport compounds (siderophores) as chelating agents. In Martell AE, Anderson WF, Badman DG (eds): Development of Iron Chelators for Clinical Use. New York: Elsevier/ North-Holland, 1981.
32. Modell B, Berdoukas V: The Clinical Approach to Thalassemia. New York: Grune and Stratton, 1984.
33. Keberle H: The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 119:758, 1964.
34. Yordanova E, Perfanov K, Slivkova L: The influence of desferrioxamine B on the activity of some iron containing enzymes in vitro. Folia Hematol 94:350, 1970.
35. Kattamis C, Fitsialos J, Sinopoulou C: Oral desferrioxamine in young patients with thalassemia. Lancet i:51, 1981.
36. Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C: Studies of desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 42:547, 1979.
37. Propper RD, Shurin SB, Nathan DG: Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 294:1421, 1976.
38. Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, Rosenthal A, Nathan DG: Continuous subcutaneous administration of desferrioxamine in patients with iron overload. N Engl J Med 297:418, 1977.
39. Modell B: Advances in the use of iron chelating agents for the treatment of iron overload. In Brown EB (ed): Progress in Hematology, Vol. XI. New York: Grune & Stratton Inc., 1979, p 267.
40. Brown EB: Candidate chelating drugs: Where do we stand? In Martell AE, Anderson WF, Badman DG (eds): Development of Iron Chelators for Clinical Use. New York: Elsevier/North-Holland, 1981.
41. Pippard MJ, Callender ST, Weatherall DJ: Intensive iron chelation therapy with desferrioxamine in iron-loading anaemias. Clin Sci Mol Med 54:99, 1978.
42. Grady RW, Peterson CM, Jones RL, Graziano JH, Bhargava KK, Berdoukas VA, Kokkini G, Loukopoulos D, Cerami A: Rhodotorulic acid-investigation of its potential as an iron chelating drug. J Pharmacol Exp Ther 209:342, 1979.
43. Baker E, Wong A, Peter H, Jacobs A: Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic. Br J Haematol 81:424, 1992.
44. Hoyes KP, Porter JB: Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol 85:393, 1993.
45. al Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV: Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 89:403, 1995.
46. Kontoghiorghes GJ, Evans RW: Site specificity of iron removal from transferrin by α-ketohydroxypyridone chelators. Fed Eur Biochem Soc Lett 189:141, 1985.
47. al Refaie FN, De-Silva CE, Wonke B, Hoffbrand AV: Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload. J Clin Pathol 48:110, 1995.
48. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB: The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 271: 20291, 1996.
49. Kontoghiorghes GJ. Iron mobilisation from ferritin using α-oxohydroxy heteroaromatic chelators. Biochem J 233:299, 1986.
50. Harrison PM, Arosio P: The ferritins: Molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275:161, 1996.
51. Berkovitch M, Laxer RM, Inman R, Koren G, Pritzker KP, Fritzler MJ, Olivieri NF: Arthropathy in thalassemic patients receiving deferiprone. Lancet 343:1471, 1994.
52. Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland RA, Koren G, Olivieri NF: Iron balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 83:2329, 1994.
53. Kersten MJ, Lange R, Smeets ME, Vreugdenhil G, Roozendaal KJ, Lameijer W, Goudsmit R: Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial. Ann Hematol 73:247, 1996.
54. Ponka P, Borova J, Neuwirt J, Fuchs O: Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. Fed Eur Biochem Soc Lett 97:317, 1979.
55. Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E: A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 586:278, 1979.
56. Hoy T, Humphreys J, Jacobs A, Williams A, Ponka P: Effective iron chelation following oral administration of an isoniazid pyridoxal hydrazone. Br J Haematol 43:443, 1979.
57. Cikrt M, Ponka P, Necas E, Neuwirt J: Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br J Haematol 45:275, 1980.
58. Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel S: Mechanisms of in vivo chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J Lab Clin Med 98:99, 1981.
59. Kim BK, Huebers HA, Finch CA: Effectiveness of oral iron chelators assayed in the rat. Am J Hematol 24:277, 1987.
60. Richardson DR, Hefter GT, May PM, Webb J, Baker E: Iron chelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(II), magnesium(II), and zinc(II). Biol Metals 2:161, 1989.
61. Vitolo LMW, Hefter GT, Clare BW, Webb J: Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(III) and iron(II). Inorg Chim Acta 170:171, 1990.
62. Richardson DR, Wis Vitolo ML, Hefter GT, May PM, Clare BW, Webb J, Wiliarat P: Iron chelators of the pyridoxal isonicotinoyl hydrazone class part 1. Ionisation characteristics of the ligands and their relevance to biological properties. Inorg Chim Acta 170:165, 1990.
63. 59Fe. Biochim Biophys Acta 757:306, 1983.
64. Richardson DR: Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process. Biochim Biophys Acta 1320:45, 1997.
65. Baker E, Richardson DR, Gross S, Ponka P: Evaluation of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 15:492, 1992.
66. Richardson DR, Ponka P: The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med 124:660, 1994.
67. Richardson DR, Tran E, Ponka P: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295, 1995.
68. Richardson DR, Milnes K: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents, II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 89:3025, 1997.
69. Brittenham GM: Pyridoxal isonicotinoyl hydrazone: An effective chelator after oral administration. Semin Hematol 27:112, 1990.
70. Richardson DR, Ponka P: Pyridoxal isonicotinoyl hydrazone and its analogues: Potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 131:306, 1998.
71. Grady RW, Jacobs A: The screening of potential iron chelating drugs. In: In Martell AE, Anderson WF, Badman DG (eds): Development of Iron Chelators for Clinical Use. New York: Elsevier/North-Holland, 1981, pp 133-164.
72. Pitt CG: Structure and activity relationships of iron chelating drugs. In Martell AE, Anderson WF, Badman DG (eds): Development of Iron Chelators for Clinical Use. New York: Elsevier/North-Holland, 1981, pp 105-131.
73. Hershko C, Grady RW, Link G: Phenolic ethylenediamine derivatives: A study of orally effective iron chelators. J Lab Clin Med 103:337, 1984.
74. Grady RW, Salbe AD, Hilgartner MW, Giardina PJ: Results from a phase I clinical trial of HBED. Adv Exp Med Biol 356:351, 1994.
75. Grady RW, Salbe AD, Hilgartner MW, Giardina PJ: Oral iron chelation: Further development of HBED. Blood 86(Suppl 1):484a, 1995 (abstr).
76. Thorstensen K: Hepatocytes and reticulocytes have different mechanisms for the uptake of iron from transferrin. J Biol Chem 263:16837, 1988.
77. Page MA, Baker E, Morgan EH: Transferrin and iron uptake by rat hepatocytes in culture. Am J Physiol 246:G26, 1984.
78. Trinder D, Morgan EH, Baker E: The mechanisms of iron uptake by rat fetal hepatocytes. Hepatology 6:852, 1986.
79. Richardson DR, Baker E: Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators and metabolic probes on transferrin and iron uptake. J Cell Physiol 161:160, 1994.
80. Richardson DR, Baker E: The uptake of iron and transferrin by the human melanoma cell. Biochim Biophys Acta 1053:1, 1990.
81. Breuer W, Epsztejn S, Millgram P, Cabantchik ZI: Transport of iron and other transition metals into cells as revealed by a fluorescent probe. Am J Physiol 268:1354, 1995.
82. Breuer W, Epsztejn S, Cabantchik ZI: Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J Biol Chem 270:24207, 1995.
83. Morgan EH: Membrane transport of non-transferrin-bound iron by reticulocytes. Biochim Biophys Acta 943:428, 1988.
84. Richardson DR, Ponka P: The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1331:1, 1997.
85. Ponka P, Beaumont C, Richardson DR: Function and regulation of transferrin and ferritin. Semin Hematol 35:1, 1998.
86. St. Pierre T, Richardson DR, Baker E, Webb J: A low spin iron complex in human melanoma and rat hepatoma cells and a high spin iron(II) complex in rat hepatoma cells. Biochim Biophys Acta 1135: 154, 1992.
87. Thorstensen K, Aisen P: Release of iron from diferric transferrin in the presence of rat liver membranes: No evidence of a diferric transferrin reductase. Biochim Biophys Acta 1052:29, 1990.
88. Sun IL, Navas P, Crane FL, Morre DJ, Low H: NADH diferric transferrin reductase in liver plasma NADH diferric transferrin reductase in liver plasma membrane. J Biol Chem 262:15915, 1987.
89. Thorstensen K, Romslo I: Uptake of iron from transferrin by isolated rat hepatocytes. A redox-mediated plasma membrane process? J Biol Chem 263:8844, 1988.
90. Porter JB, Singh S, Epemolu RO, Ackerman R, Huehns ER, Hider RC: Oral efficacy and metabolism of 1,2-diethyl-3-hydroxy-pyridin-4-one in thalassemia major. Blood 78(Suppl 1):207a, 1991 (abstr).